Total Visits

Views
Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: A study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group122

Total Visits Per Month

January 2024February 2024March 2024April 2024May 2024June 2024July 2024
Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: A study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group2130140

Top country views

Views
Poland62
United States42
France4
Sweden4
China3
Germany2
Ireland2
Australia1
India1

Top cities views

Views
Warsaw62
San Ramon7
Boardman5
San Diego5
Ann Arbor4
San Mateo4
Des Moines3
Mountain View3
Dublin2
Fairfield2